Payment overview · 2025
General Payments
$394.63
19 reported records · 7 companies
Healthcare provider profile · identity verified
Arun Deepak Mathur, MD
Allopathic & Osteopathic Physicians|Family Medicine · SYLVANIA, OH · NPI 1376705822
Verified facts
What the public records show
CMS Open Payments records show Arun Deepak Mathur, MD received $394.63 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.88 | 42.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.21 | 13.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.24 | 11.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.16 | 10.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.11 | 10.7% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.03 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.00 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.63 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $165.88 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.57 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.52 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 78 |
| Lisinopril | Lisinopril | 305 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 49 |
| Simvastatin | Simvastatin | 178 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 47 |
| Omeprazole | Omeprazole | 174 | 45 |
| Metformin Hcl | Metformin Hcl | 171 | 51 |
| Furosemide | Furosemide | 168 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 41 |
| Losartan Potassium | Losartan Potassium | 139 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 38 |
| Trazodone Hcl | Trazodone Hcl | 134 | 31 |
| Gabapentin | Gabapentin | 132 | 36 |
| Allopurinol | Allopurinol | 131 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 34 |
| Meloxicam | Meloxicam | 117 | 32 |
| Buspirone Hcl | Buspirone Hcl | 98 | 24 |
| Alprazolam | Alprazolam | 96 | 20 |
| Atenolol | Atenolol | 95 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 17 |
| Eliquis | Apixaban | 75 | 16 |
| Montelukast Sodium | Montelukast Sodium | 73 | 17 |
| Famotidine | Famotidine | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 29 |
| Azithromycin | Azithromycin | 69 | 56 |
| Metformin Hcl Er | Metformin Hcl | 68 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 17 |
| Prednisone | Prednisone | 62 | 47 |
| Carvedilol | Carvedilol | 60 | 12 |
| Ozempic | Semaglutide | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 22 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Ezetimibe | Ezetimibe | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 18 |
| Colchicine | Colchicine | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Spironolactone | Spironolactone | 38 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 13 |
| Irbesartan | Irbesartan | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Cephalexin | Cephalexin | 18 | 18 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.63 · 19 records | ABBVIE INC. | AREXVY, Cologuard Collection Kit, JARDIANCE, NURTEC ODT, Ozempic, Prolastin-C Liquid, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error